Compare BPRN & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BPRN | RNA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.3M | 227.6M |
| IPO Year | 2022 | 2025 |
| Metric | BPRN | RNA |
|---|---|---|
| Price | $35.67 | $13.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | 7.5K | ★ 366.4K |
| Earning Date | 04-24-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 74.84 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.96 | $88.12 |
| Revenue Next Year | $6.13 | $18.11 |
| P/E Ratio | $13.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.25 | $11.95 |
| 52 Week High | $37.99 | $73.06 |
| Indicator | BPRN | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 14.17 |
| Support Level | $35.54 | $11.95 |
| Resistance Level | $36.83 | $72.89 |
| Average True Range (ATR) | 0.70 | 0.51 |
| MACD | 0.29 | 1.89 |
| Stochastic Oscillator | 86.53 | 10.96 |
Princeton Bancorp Inc is a full-service financial institution providing personal and business banking services, including checking and savings accounts, as well as a range of lending products such as residential, commercial, construction, and consumer loans, including home equity loans and lines of credit. The Bank operates branches and conducts loan origination activities in areas of the New York City metropolitan area. Its loan portfolio is segmented into commercial real estate (including owner-occupied, non-owner-occupied, and multi-family properties), construction loans (mainly for residential developments), commercial and industrial loans (for business purposes), residential real estate loans (secured by one-to-four family properties), and consumer/HELOC loans.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.